Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2023-10-16 00:00:00+00:00 | ABBV | Notable Monday Option Activity: MRTN, ABBV, GILD | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Marten Transport Ltd (Symbol: MRTN), where a total of 1,085 contracts have traded so far, representing approximately 108,500 underlying shares. That amounts to about 46.2% of MRTN's average daily trading volume ... |
2023-10-15 00:00:00+00:00 | ABBV | AbbVie : Phase 3 Study Of Skyrizi In Crohn's Disease Meets All Primary And Secondary Endpoints | (RTTNews) - AbbVie (ABBV) presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (Skyrizi, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereafter) compared to ustekinumab (STELARA, I... |
2023-10-13 00:00:00+00:00 | ABBV | Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals | Eli Lilly LLY announced encouraging data from the phase III VIVID-1 study, which evaluated its IL-23p19 antibody mirikizumab for adult patients with moderate-to-severe Crohn’s disease (“CD”).
The VIVID-1 study achieved its co-primary and all major secondary endpoints. Mirikizumab demonstrated clinical remission and end... |
2023-10-13 00:00:00+00:00 | ABBV | See Which Of The Latest 13F Filers Holds AbbVie | At Holdings Channel, we have reviewed the latest batch of the 26 most recent 13F filings for the 09/30/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 21 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... |
2023-10-13 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study | AbbVie ABBV announced positive results from its mid-stage study evaluating Rinvoq (upadacitinib) in a new indication. The phase IIb study evaluated the 6 mg, 11 mg and 22 mg dose strengths of Rinvoq in adult patients with non-segmental vitiligo (NSV) compared with placebo.
The study met its primary endpoint of the perc... |
2023-10-13 00:00:00+00:00 | ABBV | ABBV Stock: Buy for the Yield, Hold for This Other Reason | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
From late spring through much of the summer, AbbVie (NYSE:ABBV) stock encountered a fair bit of turbulence.
With sales of the big pharma firm’s flagship drug Humira dropping, investors bailed on ABBV stock, fearful of continued poor results ahead.
However, ... |
2023-10-12 00:00:00+00:00 | ABBV | AbbVie: Upadacitinib Phase 2b Study In Non-segmental Vitiligo Meets Primary Goal | (RTTNews) - AbbVie (ABBV) announced Thursday that its Phase 2b study evaluating upadacitinib (RINVOQ) in adults with non-segmental vitiligo or NSV met the primary endpoint. Based on the data, the company is advancing its clinical program of upadacitinib in vitiligo to Phase 3.
NSV is the most common form of vitiligo, a... |
2023-10-12 00:00:00+00:00 | ABBV | Billionaire Paul Tudor Jones Predicts a Recession in Early 2024. Here's What It Could Mean for Stocks. | Paul Tudor Jones II built a fortune currently worth over $8 billion. Much of his success is due to shrewd trades on currencies and interest rate moves. His Tudor Investment hedge fund is also heavily invested in stocks, with more than 50 equity positions, in addition to several call and put options on individual stocks... |
2023-10-12 00:00:00+00:00 | ABBV | Morgan Stanley Maintains Abbvie (ABBV) Overweight Recommendation | Fintel reports that on October 11, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 16.05% Upside
As of October 5, 2023, the average one-year price target for Abbvie is 173.32. The forecasts range from a low of 136.35 to a high of $215.25. ... |
2023-10-11 00:00:00+00:00 | ABBV | XLV, ABBV, TMO, PFE: Large Outflows Detected at ETF | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $203.2 million dollar outflow -- that's a 0.5% decrease week over week (from 294,570,000 to 293,02... |
2023-10-11 00:00:00+00:00 | ABBV | AbbVie: Three Ongoing Phase 3 Studies Show Long-term Efficacy Of RINVOQ | (RTTNews) - AbbVie (ABBV) reported new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further showed the long-term efficacy and safety profile of RINVOQ among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks.
In the Measure Up 1, Mea... |
2023-10-11 00:00:00+00:00 | ABBV | 3 Absurdly Cheap Dividend Stocks to Buy and Hold for Years | A good way to maximize your potential returns is by focusing on cheap stocks that also pay dividends. That way, you collect a recurring payout while also setting yourself up for some attractive profits down the road. Three stocks that tick off both checkmarks for investors are Verizon Communications (NYSE: VZ), Cisco S... |
2023-10-11 00:00:00+00:00 | ABBV | The 3 Best Defensive Stocks for Nervous Investors | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Nervous investors are turning to defensive stocks, and there’s plenty of reason to be among their ranks. The U.S. Federal Reserve’s continuing battle to control inflation is the primary reason catalyzing increasing nervousness. A few weeks ago, the Fed sign... |
2023-10-10 00:00:00+00:00 | ABBV | Ex-Dividend Reminder: American Eagle Outfitters, Foot Locker and AbbVie | Looking at the universe of stocks we cover at Dividend Channel, on 10/12/23, American Eagle Outfitters, Inc. (Symbol: AEO), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. American Eagle Outfitters, Inc. will pay its quarterly dividend of... |
2023-10-10 00:00:00+00:00 | ABBV | 3 Dividend Kings Every Investor Should Own to Survive a Market Crash | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividend stocks have proved time and again to be a superior investing strategy. We all want capital appreciation, or to see our stocks grow in value over time, but dividends are what really drive excess returns.
Analysts at JPMorgan Chase (NYSE:JPM) studied... |
2023-10-10 00:00:00+00:00 | ABBV | Three Stocks To Help You Through the Financial Roller Coaster! | The world's eyes are on the Middle East again during one of the darkest hours of the region. Tensions broke into declarations of armed conflict as Hamas, the militant group that holds the Gaza Strip, launched an unprecedented attack on Israel, with the latter promising “significant military steps” as retaliation. This ... |
2023-10-09 00:00:00+00:00 | ABBV | 2 Magnificent Dividend Stocks to Buy Hand Over Fist in October | Investing in stocks may not look particularly appealing at the moment, given that the 10-year U.S. Treasury bond is offering a near 5% annualized yield. After all, most stocks outside the areas of artificial intelligence and weight-loss care have lost ground over the last two years because of various economic and geopo... |
2023-10-09 00:00:00+00:00 | ABBV | GCOW: An ETF for Dividend and Free Cash Flow Lovers | The Pacer Global Cash Cows Dividend ETF (BATS:GCOW) offers investors a nice mix of domestic and international companies that generate strong free cash flows, and it sports an attractive 5.9% dividend yield. Let’s take a deeper dive into this $1.6 billion ETF from Pacer and find out whether it’s an attractive opportunit... |
2023-10-09 00:00:00+00:00 | ABBV | AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing | AbbVie (ABBV) closed the latest trading day at $149.11, indicating a +0.59% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.63%. Meanwhile, the Dow experienced a rise of 0.59%, and the technology-dominated Nasdaq saw an increase of 0.39%.
The drugmaker's shares hav... |
2023-10-06 00:00:00+00:00 | ABBV | AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker | AbbVie ABBV announced that it is exercising its exclusive right and acquiring private biotech company Mitokinin, which is making a novel treatment for Parkinson's Disease (“PD”).
Mitokinin’s lead pipeline compound is a selective PINK1 activator that addresses mitochondrial dysfunction, which plays an instrumental role ... |
2023-10-06 00:00:00+00:00 | ABBV | Should You Load Up On This 1 Dividend Stock? | There are excellent reasons to invest in dividend stocks beyond their regular payouts. Growing a dividend requires companies to deliver solid financial results regularly, and the longer a corporation can keep things going, the more it says about the strength of its operations. Furthermore, investors who choose to reinv... |
2023-10-06 00:00:00+00:00 | ABBV | Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates | This week, Eli Lilly LLY announced a deal to take over POINT Biopharma for approximately $1.4 billion. Sanofi SNY in-licensed co-development and commercialization rights to Teva’s immunology candidate. Novartis NVS announced positive top-line data from a late-stage study on pipeline candidate iptacopan in patients with... |
2023-10-05 00:00:00+00:00 | ABBV | Retirement Royalty: 3 Dividend Aristocrats for a Steady Income Stream | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividend investing will always stay in style. While the market moves in cycles of ups and downs, dividend investing offers income even during prolonged market downturns. This reliable income has garnered the interest and love of most long-term investors due... |
2023-10-04 00:00:00+00:00 | ABBV | 7 Top Healthcare Stocks That Pay Dividends | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Facing an uncertain market environment, investors ought to consider the top healthcare stocks that pay dividends. Sure, the Federal Reserve may be in a position to facilitate a soft landing for the economy, per bullish analysts. Genuinely, I hope that’s the... |
2023-10-04 00:00:00+00:00 | ABBV | 3 High-Yielding Dividend Growth Stocks That Have Increased Their Payouts by 50% in 5 Years | If you're investing in a dividend stock, there's more than just the yield and the payout ratio to consider. It's also important to look at dividend increases -- whether the company has been making them in the past and is likely to continue doing so in the future. That's because if dividend payments grow, you'll be coll... |
2023-10-03 00:00:00+00:00 | ABBV | 5 Dividend Growth Stocks With Upside To Analyst Targets | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2023-10-02 00:00:00+00:00 | ABBV | SPHQ, V, ABBV, MRK: Large Inflows Detected at ETF | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500— Quality ETF (Symbol: SPHQ) where we have detected an approximate $84.1 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 116,410,000 ... |
2023-10-02 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | AbbVie (ABBV) closed the most recent trading day at $148.25, moving -0.54% from the previous trading session. This change lagged the S&P 500's daily gain of 0.01%. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq gained 0.67%.
Coming into today, shares of the drugmaker had gained 0.58% in the past month.... |
2023-10-02 00:00:00+00:00 | ABBV | Boehringer launches unbranded Humira biosimilar at 81% discount | By Mariam Sunny and Patrick Wingrove
Oct 2 (Reuters) - Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's ABBV.N Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug.
The company in July launched a branded biosimilar, Cyltezo, priced at a ... |
2023-10-02 00:00:00+00:00 | ABBV | Analysts Anticipate NOBL Will Reach $102 | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares S&P 500 Dividend Aris... |
2023-10-02 00:00:00+00:00 | ABBV | Drugmakers sign on to negotiate Medicare prices under protest | By Michael Erman and Patrick Wingrove
Oct 2 (Reuters) - All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen AMGN.O and Novartis NOVN.S, said they signed on to participate in the talks by the Oct. 1 deadline.
The pe... |
2023-10-02 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J | For Immediate Release
Chicago, IL – October 2, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, Lilly LLY, San... |
2023-10-02 00:00:00+00:00 | ABBV | 3 Top Stocks to Buy in October and Hold Forever | Healthcare in the United States is big business: Experts believe the system could generate more than $6 trillion in annual spending by 2030. That's an opportunity for investors to find the key players that can help grow a portfolio.
But there are so many companies in the sector, including those in medical devices, phar... |
2023-10-01 00:00:00+00:00 | ABBV | These Market Experts See a Downturn Coming: 2 Defensive Index Funds That Are Proven Moneymakers to Buy Now | Inflation reached a four-decade high in 2022 and the Federal Reserve responded by raising its benchmark interest rate at its fastest pace since the 1980s. Initially, many experts cried recession as prices soared and credit conditions tightened across the economy. Some have since recanted their forecasts, but others rem... |
2023-09-30 00:00:00+00:00 | ABBV | Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Clinical trials are a difficult and grueling process for companies. The FDA and other regulatory agencies require the highest possible standards in order to approve new drugs. To meet those standards, companies must spend exorbitant sums recruiting patients... |
2023-09-30 00:00:00+00:00 | ABBV | 3 Magnificent Dividend Stocks to Buy in October | There's no better time than October to invest in high-quality dividend stocks. That's because the new month offers a chance to get those dividend payments flowing sooner rather than later.
Three Motley Fool contributors believe they've identified magnificent dividend stocks to buy in October. Here's why they chose AbbV... |
2023-09-29 00:00:00+00:00 | ABBV | Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs | This week, the European Commission granted marketing approval to AbbVie’s ABBV Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The FDA approved Lilly’s LLY diabetes drug, Jardiance (empagliflozin), for expanded use in chronic kidney disease (“CKD”).
The FDA also accep... |
2023-09-29 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this drugmaker have returned +3.6% over the past month versus the Zacks S&P 500 composite's -2.9% change. The Zacks ... |
2023-09-29 00:00:00+00:00 | ABBV | US judge refuses to block Medicare from negotiating drug prices | (Adds detail from the ruling in paragraphs 3-6)
By Brendan Pierson
Sept 29 (Reuters) - The U.S. government's Medicare health insurance program can begin negotiating prices for some prescription drugs this fall under a new program, a federal judge ruled on Friday, vindicating one of President Joe Biden's signature initi... |
2023-09-29 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights Oracle, AbbVie, Lowe's Companies, Ecolab and Motorola Solutions | For Immediate Release
Chicago, IL – September 29, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oracle Corp. ORCL, AbbVi... |
2023-09-29 00:00:00+00:00 | ABBV | AbbVie's blood cancer combo therapy fails in late-stage study | Adds details throughout
Sept 29 (Reuters) - AbbVie ABBV.N said on Friday a late-stage study of its experimental combination therapy failed to show meaningful increase in the survival of patients with a form of blood cancer without the disease worsening.
The combination of AbbVie's Venclyxto and a steroid dexamethasone ... |
2023-09-29 00:00:00+00:00 | ABBV | Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 Years | No return is guaranteed in the stock market. However, investors can have a high degree of certainty when it comes to dividend payments from quality companies.
Diamondback Energy (NASDAQ: FANG) offers a combination of a stable dividend and upside exposure to high energy prices. NextEra Energy Partners (NYSE: NEP) passes... |
2023-09-29 00:00:00+00:00 | ABBV | AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint | (RTTNews) - AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments.
The data d... |
2023-09-29 00:00:00+00:00 | ABBV | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | Designed to provide broad exposure to the Style Box - Large Cap Value category of the market, the WisdomTree U.S. High Dividend ETF (DHS) is a smart beta exchange traded fund launched on 06/16/2006.
What Are Smart Beta ETFs?
Products that are based on market cap weighted indexes, which are strategies designed to reflec... |
2023-09-28 00:00:00+00:00 | ABBV | Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views? | When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Let's take a look at what these Wall Street heavyweights have ... |
2023-09-26 00:00:00+00:00 | ABBV | Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In the dynamic investment realm, one sector that continues to stand out is the area of biotech stocks. Though risky, especially when assessing established firms with market-ready drugs and vast research and development (R&D), the rewards can be significant.... |
2023-09-26 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL | AbbVie ABBV and partner Genmab GMAB announced that the European Commission has granted conditional marketing authorization to epcoritamab for treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). DLBCL is a common, aggressive and fast-growing form of non-Hodgkin's lymphoma (NHL).
Epcoritamab will... |
2023-09-26 00:00:00+00:00 | ABBV | Clorox Pullback Presents a Chance to Clean Up on a 3.6% Dividend | Since The Clorox Company (NYSE: CLX) rode a pandemic ‘clean freak’ wave to nearly $240 per share in August 2021, its market value has been bleached by over $13 billion.
The dirty truth? Clorox’s 44% two-year plunge has created an opportunity to own a defensive stock with a shiny dividend.
The consumer products mainsta... |
2023-09-25 00:00:00+00:00 | ABBV | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | AbbVie (ABBV) closed the most recent trading day at $154.65, moving +1.25% from the previous trading session. This change outpaced the S&P 500's 0.4% gain on the day. Elsewhere, the Dow gained 0.13%, while the tech-heavy Nasdaq added 0.45%.
Coming into today, shares of the drugmaker had gained 4.12% in the past month. ... |
2023-09-25 00:00:00+00:00 | ABBV | AbbVie, Genmab: EU Approves TEPKINLY For Adults With R/R Diffuse Large B-cell Lymphoma | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced Monday that the European Commission has granted conditional marketing authorization for TEPKINLY (epcoritamab) for adults with relapsed or refractory or R/R diffuse large B-cell lymphoma or DLBCL.
TEPKINLY is being co-developed by AbbVie and Genmab as part of th... |
2023-09-25 00:00:00+00:00 | ABBV | Argenx's 28% Surge & Promising Product Propel Investor Confidence | If you want to get an isolated view of a constructive base taking shape in a strong stock, take a look at the Argenix SE (NASDAQ: ARGX) chart.
The stock gapped up nearly 28% on July 17, after announcing better-than-expected results from a clinical trial of its treatment for patients suffering from a progressive condit... |
2023-09-22 00:00:00+00:00 | ABBV | Noteworthy ETF Outflows: IVW, ABBV, TMO, DHR | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $75.9 million dollar outflow -- that's a 0.2% decrease week over week (from 494,800,000 to 493,700,000). Among ... |
2023-09-21 00:00:00+00:00 | ABBV | 3 Bargain Stocks to Buy in a Market That's Priced for Perfection | Stock valuations are at historically high levels. However, that doesn't mean you can't find stocks worth buying.
Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
A... |
2023-09-21 00:00:00+00:00 | ABBV | Interesting ABBV Put And Call Options For November 3rd | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the November 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new November 3rd contracts and identified one put and one call contract of particular interest.
The put c... |
2023-09-21 00:00:00+00:00 | ABBV | Only 7 Large-Cap Dividend Kings Yield Over 3%. Here's My Top Pick to Buy Now. | If you're an income investor, you may have heard tales of mighty companies that have raised their payouts no matter the economic cycle. Only 49 companies over the past 50 years have managed to accomplish this monumental feat. But the ancient lore can be misleading as far fewer companies have a high yield and a market c... |
2023-09-20 00:00:00+00:00 | ABBV | Flee to Healthcare Stocks if Recession Rears its Head? | If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.50% in the past month, lagging the S&P 500.
The top components within the sector are Eli Lilly & Co. (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Merc... |
2023-09-20 00:00:00+00:00 | ABBV | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | The WisdomTree U.S. High Dividend ETF (DHS) was launched on 06/16/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.18 billion, making it one of the average siz... |
2023-09-19 00:00:00+00:00 | ABBV | The Top 7 Underrated Dividend Stocks Yielding 3% or More | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Looking for dividend stocks yielding 3% or more might seem pretty specific. Remember, though, the logic behind investing in underrated stocks is straightforward: Buy low and sell high in order to see a healthy return on your investment.
Making smart investm... |
2023-09-18 00:00:00+00:00 | ABBV | Should You Follow Warren Buffett's Lead and Sell HPQ Stock? | Berkshire Hathaway (BRK.B) - the conglomerate led by legendary value investor Warren Buffett - sold almost 5.5 million shares of HP (HPQ) last week. The announcement took the market by surprise, just as the initial news of Berkshire buying a stake in HP did last year.
Buffett has largely shied away from tech stocks - a... |
2023-09-18 00:00:00+00:00 | ABBV | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | In the latest trading session, AbbVie (ABBV) closed at $153.94, marking a +1.2% move from the previous day. This change outpaced the S&P 500's 0.07% gain on the day. Meanwhile, the Dow gained 0.02%, and the Nasdaq, a tech-heavy index, added 0.01%.
Coming into today, shares of the drugmaker had gained 1.32% in the past ... |
2023-09-18 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned +1.3%, compared to the Zacks S&P 500 composite's +0.4% change. During thi... |
2023-09-18 00:00:00+00:00 | ABBV | Allergan Aesthetics: Second Phase 3 Study With OnabotulinumtoxinA Meets Endpoints | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), reported positive topline results from the second of three Phase 3 clinical studies evaluating onabotulinumtoxinA for the treatment of moderate to severe platysma prominence associated with platysma muscle activity. The company said all primary and secondary en... |
2023-09-17 00:00:00+00:00 | ABBV | Abbvie (ABBV) Declares $1.48 Dividend | Abbvie said on September 8, 2023 that its board of directors declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Previously, the company paid $1.48 per share.
Shares must be purchased before the ex-div date of October 12, 2023 to qualify for the dividend. Shareholders of record as of October 13... |
2023-09-15 00:00:00+00:00 | ABBV | US Chamber of Commerce urges judge to block Medicare drug pricing program | By Nate Raymond
Sept 15 (Reuters) - A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with pharmaceutical companies for selected costly drugs.
Jeffrey Bucholtz, the business gro... |
2023-09-15 00:00:00+00:00 | ABBV | Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar? | If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the SPDR S&P Dividend ETF (SDY), a passively managed exchange traded fund launched on 11/08/2005.
The fund is sponsored by State Street Global Advisors. It has amassed assets over $21.40 billion, making i... |
2023-09-15 00:00:00+00:00 | ABBV | Sandoz dials up product launch plans ahead of market debut | By Ludwig Burger and Paul Arnold
FRANKFURT, Sept 15 (Reuters) - Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland's Novartis NOVN.S works to enhance its investor appeal ahead of its market debut next month.
Its launch ambitions com... |
2023-09-15 00:00:00+00:00 | ABBV | Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More | This week, the FDA approved and the U.S. Centers for Disease Control and Prevention (CDC) recommended the broad use of updated COVID-19 vaccines of Pfizer PFE/BioNTech and Moderna MRNA. Novo Nordisk’s NVO board of directors approved the previously announced two-for-one split of its shares and American Depositary Receip... |
2023-09-15 00:00:00+00:00 | ABBV | 2 Dividend Kings to Buy on the Dip and Hold Forever | The elite club of Dividend Kings arguably stands out as the market's most prestigious group of dividend payers. Companies must have raised their payouts for at least 50 consecutive years to join, a feat requiring an incredibly solid business. The strength of their underlying operations makes many Dividend Kings attract... |
2023-09-14 00:00:00+00:00 | ABBV | Health Care Sector Update for 09/14/2023: BIOL, CMND, OKYO, HARP, ABBV | Health care stocks were higher late Thursday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.4%.
The iShares Biotechnology ETF (IBB) was climbing 0.6%.
In corporate news, Biolase (BIOL) shares slumped 40% after the company said late Wednesday it priced a $4.5 mi... |
2023-09-14 00:00:00+00:00 | ABBV | Health Care Sector Update for 09/14/2023: CMND, OKYO, HARP, ABBV | Health care stocks were higher Thursday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.4%.
The iShares Biotechnology ETF (IBB) was climbing 0.6%.
In corporate news, Clearmind Medicine (CMND) stock slumped 56% after the company said Thursday it priced its US-exc... |
2023-09-14 00:00:00+00:00 | ABBV | Noteworthy ETF Outflows: XLV, MRK, ABBV, TMO | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $611.0 million dollar outflow -- that's a 1.5% decrease week over week (from 301,770,000 to 297,17... |
2023-09-13 00:00:00+00:00 | ABBV | "Blockbuster Status": 3 Bios to Buy and Hold | Profitability in the Biotech Industry is Hard to Come By
The biotech sector is notorious for its sky-high research and development (R&D) costs, regulatory hurdles, and lengthy timelines to bring a drug or therapy to market. Many drugs fail clinical trials while biotech companies set others aside to focus on more encour... |
2023-09-13 00:00:00+00:00 | ABBV | ABBV Crosses Above Key Moving Average Level | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $150.27, changing hands as high as $152.40 per share. AbbVie Inc shares are currently trading up about 1.3% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving aver... |
2023-09-13 00:00:00+00:00 | ABBV | 2 Undervalued Dividend Stocks to Buy Now | If you're looking for dividend stocks that offer both attractive yields and strong growth prospects, you might want to consider AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Both of these healthcare giants have impressive track records of rewarding shareholders with consistent dividend payments and increase... |
2023-09-13 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals | AbbVie ABBV announced that its key drug, Skyrizi (risankizumab) met all primary and secondary endpoints of a head-to-head phase III study comparing the drug against J&J’s JNJ blockbuster medicine, Stelara (ustekinumab) in Crohn’s disease.
The phase III study called SEQUENCE compared Skyrizi to J&J’s Stelara for the tre... |
2023-09-12 00:00:00+00:00 | ABBV | Notable Tuesday Option Activity: BAC, ABBV, NOW | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Bank of America Corp (Symbol: BAC), where a total of 196,851 contracts have traded so far, representing approximately 19.7 million underlying shares. That amounts to about 53.1% of BAC's average daily trading volume ... |
2023-09-12 00:00:00+00:00 | ABBV | Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? | Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Before we discuss the reliability of brok... |
2023-09-12 00:00:00+00:00 | ABBV | This Proven 200% Dividend Growth Strategy Is a Peter Lynch Favorite | Let's dive into this Johnson & Johnson (JNJ) spinoff--because it shows exactly how we can tap "splits" like these to grab not one but TWO income streams growing 200%+.
Because if there's one thing we need to know about spinoffs, it's this: they're about the closest thing to a free lunch you'll find in investing. Just a... |
2023-09-12 00:00:00+00:00 | ABBV | High Yield, Low Beta Stocks to Buy for the Next Market Meltdown | The market's fear indicator, the VIX index, is bobbing along at long-term lows and gives little indication of a looming correction, but investors should assume one is brewing. The index is down at its lows because the recession that was supposed to happen in 2023 never materialized. What has materialized is the persist... |
2023-09-11 00:00:00+00:00 | ABBV | AbbVie (ABBV) Gains But Lags Market: What You Should Know | In the latest trading session, AbbVie (ABBV) closed at $149.04, marking a +0.01% move from the previous day. The stock lagged the S&P 500's daily gain of 0.67%. Elsewhere, the Dow gained 0.25%, while the tech-heavy Nasdaq added 1.14%.
Prior to today's trading, shares of the drugmaker had lost 2.08% over the past month.... |
2023-09-11 00:00:00+00:00 | ABBV | Why AbbVie is a Top 25 SAFE Dividend Stock (ABBV) | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
Accor... |
2023-09-08 00:00:00+00:00 | ABBV | Daily Dividend Report: AMAT,ABBV,VICI,ALLE,NLY | Applied Materials today announced that its Board of Directors has approved a quarterly cash dividend of $0.32 per share payable on the company's common stock. The dividend is payable on Dec. 14, 2023 to shareholders of record as of Nov. 24, 2023.
The board of directors of AbbVie today declared a quarterly cash dividend... |
2023-09-08 00:00:00+00:00 | ABBV | Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study | Shares of Alector ALEC rose 6.8% on Thursday after management announced that it achieved the enrolment target in the phase II INVOKE-2 study on its Alzheimer’s disease (“AD”) candidate, AL002. The candidate is being co-developed with AbbVie ABBV.
Alector expects data from the study before this year’s end.
Based on this... |
2023-09-07 00:00:00+00:00 | ABBV | Weakness in Apple Weighs on Tech Stocks and Drags Broader Marker Lower | What you need to know…
The S&P 500 Index ($SPX) (SPY) Thursday closed down -0.32%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.17%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.73%.
Stocks on Thursday settled mixed, with the S&P 500 falling to a 1-1/2 week low and the Nasdaq 100 index falling to... |
2023-09-06 00:00:00+00:00 | ABBV | Notable ETF Inflow Detected - PBUS, CVX, MRK, ABBV | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco MSCI USA ETF (Symbol: PBUS) where we have detected an approximate $318.6 million dollar inflow -- that's a 11.8% increase week over week in outstanding units (from 60,380,000 to 67,4... |
2023-09-05 00:00:00+00:00 | ABBV | 3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In the grand tapestry of the investment world, one thread that continues to shine is biotech stocks to buy and hold. It’s no secret that delving into biotech investments can be incredibly challenging, even when zeroing in on established firms with market-re... |
2023-09-05 00:00:00+00:00 | ABBV | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | AbbVie (ABBV) closed at $146.10 in the latest trading session, marking a -1.42% move from the prior day. This move lagged the S&P 500's daily loss of 0.42%. At the same time, the Dow lost 0.56%, and the tech-heavy Nasdaq lost 0.08%.
Prior to today's trading, shares of the drugmaker had lost 1.42% over the past month. T... |
2023-09-05 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this drugmaker have returned -1.4% over the past month versus the Zacks S&P 500 composite's +1% change. The Zacks Large Cap... |
2023-09-04 00:00:00+00:00 | ABBV | Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now? | A smart beta exchange traded fund, the SPDR S&P Dividend ETF (SDY) debuted on 11/08/2005, and offers broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Products that are based on market cap weighted indexes, which are strategies designed to reflect a specific market segm... |
2023-09-02 00:00:00+00:00 | ABBV | Could CVS Make a Copy of Ozempic? | On Aug. 23, CVS Health (NYSE: CVS) made waves when it announced that it will be launching a new business called Cordavis that will be devoted to commercializing biosimilar medicines. If you aren't familiar, biosimilars are generic versions of biologic drugs, which tend to be newer, more complex, and more expensive comp... |
2023-09-02 00:00:00+00:00 | ABBV | 3 No-Brainer Dividend Stocks to Buy in September | When's a good time to invest in dividend stocks? Any month that has a vowel in its name.
We asked three Motley Fool contributors to identify no-brainer dividend stocks to buy in September. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD).
Dividend royalty ... |
2023-09-02 00:00:00+00:00 | ABBV | 8 Pharma Stocks Affected by New Drug Price Negotiation Rules | About a year ago, President Joe Biden signed the Inflation Reduction Act into law. Among the many things that law achieved was to give Medicare, for the first time, the ability to directly negotiate the prices it pays for some of the single-source drugs that it spends the most on each year.
Recently, the Centers for Me... |
2023-09-01 00:00:00+00:00 | ABBV | 'Barbie Botox' goes viral but doctors inject caution | By Leroy Leo
Sept 1 (Reuters) - The viral trend of "Barbie Botox" that has women as young as in their 20s rush for toxin-based procedures to mimic the looks of the movie's lead actress Margot Robbie may lead to resistance among users and hinder medical use in future, doctors cautioned.
The procedure, also known "Trap T... |
2023-09-01 00:00:00+00:00 | ABBV | Pharma Stock Roundup: J&J's New '23 View After Kenvue Separation, Regulatory Updates | This week, J&J JNJ updated its financial guidance for 2023 after it completed the spin-out of its Consumer Health unit, Kenvue. The European Commission approved Merck’s MRK blockbuster cancer drug Keytruda for the first-line treatment of certain types of patients with gastric cancer. AbbVie ABBV filed applications in t... |
2023-09-01 00:00:00+00:00 | ABBV | 5 Dividend Growth Stocks With Upside To Analyst Targets | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2023-09-01 00:00:00+00:00 | ABBV | Should You Pick Merck Stock Over Coca-Cola? | We believe that Merck stock (NYSE: MRK) and Coca-Cola stock (NYSE: KO) will offer little returns in the next three years. Although these companies are from different sectors, we compare them because they have a similar market capitalization of $260 billion to $280 billion. The decision to invest often comes down to fi... |
2023-09-01 00:00:00+00:00 | ABBV | CVS Just Made a Major New Announcement, But Should You Buy It? | On August 23, CVS Health (NYSE: CVS) made waves when it announced that it would be initiating a new subsidiary called Cordavis that will be devoted to commercializing biosimilar medications. Now, investors can look forward to the company posting a faster pace of recurring revenue growth as it brings copies of best-sell... |
2023-08-31 00:00:00+00:00 | ABBV | Sum Up The Parts: HDV Could Be Worth $117 | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core High Dividend ETF ... |
2023-08-31 00:00:00+00:00 | ABBV | Building Wealth with Spinoffs: How Adding These Gems Can Transform Your Portfolio | Imagine discovering a treasure map that leads to the chest containing the loot. Consider that the investment world has its own version of these concealed treasures: Spinoffs. These financial treasures have the potential to reshape your entire investment voyage, not just enhance your portfolio. The catch? You must look ... |
2023-08-31 00:00:00+00:00 | ABBV | The 3 Most Promising Biotech Stocks to Own Now | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards of minority voters. This commitment to economic inclusivity bodes well fo... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.